Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) Short Interest Update

Vallon Pharmaceuticals, Inc. (NASDAQ:VLON – Get Rating) saw a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 136,800 shares, a drop of 48.6% from the March 31st total of 266,000 shares. Based on an average daily trading volume, of 3,280,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 4.3% of the company’s stock are short sold.

A number of institutional investors have recently added to or reduced their stakes in VLON. Advisor Group Holdings Inc. raised its stake in Vallon Pharmaceuticals by 57.4% in the third quarter. Advisor Group Holdings Inc. now owns 6,890 shares of the company’s stock valued at $50,000 after buying an additional 2,512 shares during the last quarter. Laidlaw Wealth Management LLC purchased a new position in shares of Vallon Pharmaceuticals in the fourth quarter worth about $121,000. Finally, Geode Capital Management LLC raised its stake in shares of Vallon Pharmaceuticals by 84.0% in the third quarter. Geode Capital Management LLC now owns 24,134 shares of the company’s stock worth $175,000 after purchasing an additional 11,018 shares during the last quarter. Institutional investors own 5.55% of the company’s stock.

Vallon Pharmaceuticals stock opened at $1.24 on Friday. The stock has a 50-day moving average of $3.77 and a two-hundred day moving average of $5.06. Vallon Pharmaceuticals has a one year low of $1.13 and a one year high of $3.45. The stock has a market cap of $8.45 million, a PE ratio of -0.86 and a beta of -2.71.

Vallon Pharmaceuticals (NASDAQ:VLON – Get Rating) last released its quarterly earnings results on Monday, February 14th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.24). Equities research analysts predict that Vallon Pharmaceuticals will post -0.99 EPS for the current fiscal year.

About Vallon Pharmaceuticals (Get Rating)

Vallon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel abuse-deterrent medications for central nervous system disorders. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.

Featured Stories